Scribe Therapeutics (SCTX) Stock Price, News & Analysis

Company Overview

Scribe Therapeutics is a biotechnology company focused on developing CRISPR-based gene-editing technologies and potential genetic medicines. Its platform uses engineered CRISPR systems designed to make targeted changes to DNA, with research aimed at applications across multiple disease areas.

Founded in 2017 and based in Alameda, California, the company has pursued research and development collaborations with pharmaceutical companies, including Sanofi and Biogen. Scribe Therapeutics is privately held; I could not verify a Nasdaq listing under the symbol SCTX.

Key Stats

• Today's Range: $15.55 to $17.49
• 50-Day Range: $15.40 to $33.00
• 52-Week Range: $13.50 to $39.60
• Volume: 282,268 shs
• Average Volume: 363,927 shs
• Market Capitalization: $321.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $51.75
• Consensus Rating: Moderate Buy

Scribe Therapeutics Stock Analysis - MarketRank™

Scribe Therapeutics scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Scribe Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Scribe Therapeutics has a consensus price target of $51.75, representing about 204.6% upside from its current price of $16.99.

Amount of Analyst Coverage

Scribe Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scribe Therapeutics are expected to grow in the coming year, from ($3.68) to ($2.52) per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.83% of the float of Scribe Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Scribe Therapeutics has a short interest ratio ("days to cover") of 4.01.

Change versus previous month

Short interest in Scribe Therapeutics has recently increased by 49.47%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scribe Therapeutics does not currently pay a dividend.

Dividend Growth

Scribe Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.29

News Sentiment

Scribe Therapeutics has a news sentiment score of -0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Scribe Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for SCTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Scribe Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scribe Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Scribe Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Today: 11/12/2026
• Last Earnings: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:SCTX
• CIK: 1853921
• Web: www.scribetx.com
• Phone: (510) 454-0213
• Fax: N/A
• Employees: 82
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scribe Therapeutics: $51.75
• High Price Target: $60.00
• Low Price Target: $37.00
• Potential Upside/Downside: +204.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.57
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: $51.17 million
• Price / Sales: 6.29
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,930,000
• Free Float: N/A
• Market Cap: $321.62 million
• Optionable: N/A
• Beta: N/A